CELL INTELLIGENCE · 肿瘤细胞治疗研究

FOXP1 敲低重编程 Th9 CAR-T 细胞以克服抗原逃逸

FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.

提升 T 细胞抗氧化能力：克服实体瘤免疫抑制的一种策略性方法

Boosting T cell antioxidant capacity: A strategic approach to overcome immunosuppression in solid tumors.

TCR-JANUS 衔接蛋白实现双特异性靶向以克服 TCR-T 细胞治疗中的肿瘤异质性

TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy.

体内全基因组 CRISPR 筛选鉴定 FOXR1 为 CD8(+) T 细胞抗肿瘤免疫的抑制因子

In vivo genome-wide CRISPR screens identify FOXR1 as a suppressor of CD8(+) T cell antitumor immunity.

体内 CAR-T 用于实体瘤：面临体外 CAR-T 的所有挑战及更多

In vivo CAR-T for solid tumors: facing all the challenges of ex vivo CAR-T and more.

儿童实体瘤的嵌合抗原受体（CAR）-T 细胞疗法：当前突破、困境与策略

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.

体内 CAR-T 细胞生成：递送平台、临床进展与转化障碍

In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers.

外周血单核细胞衍生的 eNK 细胞通过装载 16Fc21——一种针对 NK 细胞的新型双特异性融合蛋白——被武装并促进了对肿瘤的 CAR 样反应

PBMC-derive eNK cells was armed and promoted CAR-like response against tumors through armed with 16Fc21, a novel bispecific fusion protein for NK cell

我们证实，这种新型联合疗法能够有效提高 NK 细胞在体内的存活和增殖能力，为增强其体内治疗效果提供了一种更安全、更有效的方法。该方法为解决 PBMC 来源 NK 细胞体外基因修饰繁琐及其体内治疗效果不足的难题提供了解决方案。

镁功能化水凝胶递送 CAR-T 细胞增强腹膜转移治疗

Delivery of CAR T Cells in a Magnesium-Functionated Hydrogel Boosts Peritoneal Metastasis Treatment.

免疫功能低下宿主中耐药革兰阴性感染的新型抗生素：从关键试验到高风险实践

Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice.